Content about tobramycin

November 22, 2013

Cornerstone Therapeutics has added specialty pharmacy Diplomat to its limited-distribution network for a newly approved treatment for cystic fibrosis, Diplomat said Friday.

FLINT, Mich. — Cornerstone Therapeutics has added specialty pharmacy Diplomat to its limited-distribution network for a newly approved treatment for cystic fibrosis, Diplomat said Friday.

Diplomat will distribute Bethkis (tobramycin inhalation solution), which received Food and Drug Administration approval in October for treating chronic bacterial lung infections caused by P. aeruginosa in cystic fibrosis patients.

November 22, 2013

Teva Pharmaceutical Industries has launched its generic version of a drug for patients with cystic fibrosis, the Israeli drug maker said Thursday.

JERUSALEM — Teva Pharmaceutical Industries has launched its generic version of a drug for patients with cystic fibrosis, the Israeli drug maker said Thursday.

Teva announced the launch of tobramycin inhalation solution, a generic version of Novartis' drug Tobi. The Food and Drug Administration approved Teva's product last month. The drug is used to treat CF in patients whose lungs contain bacteria called Pseudomonas aeroginosa.

Tobi had sales of about $350 million during the 12-month period that ended in June, according to IMS Health.

 

October 15, 2013

The Food and Drug Administration has approved a new generic drug from Teva Pharmaceutical Industries for treating eye infections, the company said.

JERUSALEM — The Food and Drug Administration has approved a new generic drug from Teva Pharmaceutical Industries for treating eye infections, the company said.

The Israeli drug maker announced the approval of the antibiotic drug tobramycin inhalation solution, a generic version of Novartis' Tobi.

Tobi has sales of about $350 million during the 12-month period that ended in June, according to IMS Health.

 

March 25, 2013

The Food and Drug Administration has approved a treatment for managing a type of bacterial infection in patients with cystic fibrosis.

EAST HANOVER, N.J. — The Food and Drug Administration has approved a treatment for managing a type of bacterial infection in patients with cystic fibrosis.

Swiss drug maker Novartis announced the approval of Tobi Podhaler (tobramycin inhalation powder) for managing cystic fibrosis patients with Pseudomonas aeruginosa, or Pa bacteria, in the lungs.

September 6, 2012

A panel of Food and Drug Administration experts is recommending that the agency approve an experimental drug for cystic fibrosis made by Novartis, the Swiss drug maker said.

EAST HANOVER, N.J. — A panel of Food and Drug Administration experts is recommending that the agency approve an experimental drug for cystic fibrosis made by Novartis, the Swiss drug maker said.

September 22, 2010

Eyecare company Alcon has launched a new drug for inflammatory eye conditions....

HUENENBERG, Switzerland Eyecare company Alcon has launched a new drug for inflammatory eye conditions.

 

Alcon announced the launch of TobraDex ST (tobramycin, dexamethasone ophthalmic suspension) in the 0.3%/0.5% strength. The drug is used to treat inflammatory eye conditions treatable with corticosteroids and where bacterial infection or risk of infection exists.